[1] U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44: 1249-1258.
[2] Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281: 2005-2012.
[3] Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011; 378: 169-181.
[4] Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008; 371: 1753-1760.
[5] Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013; 1: 28-34.
[6] Hu Y, Li L, Xu Y, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care. 2011; 34: 1848-1853.
[7] Consortium R. Lack of Durable Improvements in beta-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. 2019; 42: 1742-1751.
[8] Consortium R. Impact of Insulin and Metformin Versus Metformin Alone on beta-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. 2018; 41: 1717-1725.
[9] Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751population-based studies with 4.4 million participants. Lancet. 2016; 387: 1513-1530.
[10] Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012; 35:2650-2664.
[11] Leung E, Wongrakpanich S, Munshi MN. Diabetes Management in the Elderly. Diabetes Spectr. 2018; 31: 245-253.
[12] American Diabetes A. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018; 41: 917-928.
[13] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.
[14] Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443.
[15] Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009; 32: 762-768.
[16] Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014; 37: 3270-3278.
[17] Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013; 17: 491-506.
[18] Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012; 61: 1315-1322.
[19] Ihm SH, Moon HJ, Kang JG, et al. Effect of aging on insulin secretory function and expression of beta cell function-related genes of islets. Diabetes Res Clin Pract. 2007;77 Suppl 1: S150-154.
[20] Ribeiro RA, Batista TM, Coelho FM, Boschero AC, Lopes GS, Carneiro EM. Decreased beta-cell insulin secretory function in aged rats due to impaired Ca(2+) handling. Exp Physiol. 2012; 97: 1065-1073.
[21] Wang S, Sun QQ, Xiang B, Li XJ. Pancreatic islet cell autophagy during aging in rats. Clin Invest Med. 2013; 36: E72-80.
[22] Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008; 29: 351-366.
[23] Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care. 2014; 37: 1116-1123.
[24] Ceriello A, Ihnat MA. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 2010; 27: 862-867.
[25] Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. 2010; 31: 171-182.
[26] Saisho Y, Tanaka K, Abe T, Kawai T, Itoh H. Lower beta cell function relates to sustainedhigher glycated albumin to glycated hemoglobin ratio in Japanese patients with type 2 diabetes. Endocr J. 2014; 61: 149-157.
[27] Mu PW, Chen YM, Lu HY, et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2012; 28: 236-240.
[28] Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014; 37: 2108-2113.
[29] Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157: 1681-1686.